Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Patients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo. (Funded by Arrowhead Pharmaceuticals; PALISADE ClinicalTrials.gov number, NCT05089084.).
Authors
- Alexis Baass (ORCID: https://orcid.org/0000-0001-9534-1657)
- Robert A. Hegele (ORCID: https://orcid.org/0000-0003-2861-5325)
- Nicholas J. Leeper (ORCID: https://orcid.org/0000-0002-0905-2806)
- Rong Zhou (ORCID: https://orcid.org/0000-0002-4540-7336)
- Jennifer Hellawell (ORCID: https://orcid.org/0000-0001-8485-1846)
- Ira J. Goldberg (ORCID: https://orcid.org/0000-0002-8701-2201)
- Gerald F. Watts (ORCID: https://orcid.org/0000-0003-2276-1524)
- Antonio Gallo (ORCID: https://orcid.org/0000-0002-2203-6237)
- Daniel Gaudet (ORCID: https://orcid.org/0000-0002-5185-3666)
- Ma’an Muhsin
- Ann C. Mertens (ORCID: https://orcid.org/0000-0003-0989-0962)
- Robert S. Rosenson
Institutions
- Inserm (FR)
- Sorbonne Université (FR)
- Mount Sinai Hospital (US)
- Fondation pour l’innovation en Cadiométabolisme et Nutrition (FR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1056/nejmoa2409368
- Citations
- 123
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 49.45
Funders
- Arrowhead Pharmaceuticals